Big Data Is Remaking Big Pharma

Big Pharma is in a rut. The industry keeps spending more and yet making fewer scientific breakthroughs.But help is on the way. GlaxoSmithKline recently announced a radical change in R&D spending. The British drug giant will refocus on data analytics, and the link between the immune system and human disease.

It is harbinger of things to come. It is also a big opportunity for investors. GSK is trying to catch bigger trends. By studying the genetic profiles of patients with diseases, scientists are starting to understand what makes humans ill in the first place. Meanwhile, information technology is accelerating at an exponential rate. Every day, researchers use advances in machine learning and artificial intelligence to see patterns in data that were invisible only decade ago.

Author: Jon Markman


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s